Published in Physician Law Weekly, June 30th, 2004
Liability, manufacturing concerns and uncertainty about how the money will be allocated are among the reasons for the reluctance, despite the passage of the BioShield funding bill by the U.S. House and Senate. Those concerns are the subject of a conference June 9, 2004, hosted by the University of Maryland School of Law.
VaxGen President Lance K. Gordon said his...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.